| Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within … NI Paton, C Kityo, J Thompson, I Nankya, L Bagenda, A Hoppe, J Hakim, ... The lancet HIV 4 (8), e341-e348, 2017 | 82 | 2017 |
| Low-frequency drug resistance in HIV-infected Ugandans on antiretroviral treatment is associated with regimen failure F Kyeyune, RM Gibson, I Nankya, C Venner, S Metha, J Akao, ... Antimicrobial agents and chemotherapy 60 (6), 3380-3397, 2016 | 59 | 2016 |
| Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up … JG Hakim, J Thompson, C Kityo, A Hoppe, A Kambugu, JJ van Oosterhout, ... The Lancet Infectious Diseases 18 (1), 47-57, 2018 | 52 | 2018 |
| The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030 E Ndashimye, EJ Arts Infectious Diseases of Poverty 8 (04), 67-74, 2019 | 45 | 2019 |
| Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period F Kyeyune, I Nankya, S Metha, J Akao, E Ndashimye, DM Tebit, ... Aids 27 (12), 1899-1909, 2013 | 43 | 2013 |
| HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa C Kityo, J Thompson, I Nankya, A Hoppe, E Ndashimye, C Warambwa, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 75 (2), e45-e54, 2017 | 35 | 2017 |
| Addressing an HIV cure in LMIC SD Ismail, J Pankrac, E Ndashimye, JL Prodger, MR Abrahams, ... Retrovirology 18 (1), 21, 2021 | 34 | 2021 |
| Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda E Ndashimye, M Avino, F Kyeyune, I Nankya, RM Gibson, E Nabulime, ... AIDS research and human retroviruses 34 (5), 404-414, 2018 | 29 | 2018 |
| Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection K Klein, G Nickel, I Nankya, F Kyeyune, K Demers, E Ndashimye, C Kwok, ... PLoS pathogens 14 (1), e1006754, 2018 | 27 | 2018 |
| Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: observational … AJ Szubert, AJ Prendergast, MJ Spyer, V Musiime, P Musoke, ... PLoS medicine 14 (11), e1002432, 2017 | 26 | 2017 |
| First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda AFY Poon, E Ndashimye, M Avino, R Gibson, C Kityo, F Kyeyune, ... AIDS research and therapy 16 (1), 1-10, 2019 | 16 | 2019 |
| Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low-to middle-income countries RM Gibson, G Nickel, M Crawford, F Kyeyune, C Venner, I Nankya, ... Infectious diseases of poverty 6, 1-13, 2017 | 16 | 2017 |
| Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: impact in low-and middle-income settings E Ndashimye, EJ Arts International Journal of Infectious Diseases 105, 298-303, 2021 | 15 | 2021 |
| Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing … E Ndashimye, M Avino, AS Olabode, AFY Poon, RM Gibson, Y Li, ... Journal of Antimicrobial Chemotherapy 75 (12), 3525-3533, 2020 | 15 | 2020 |
| High-level resistance to bictegravir and cabotegravir in subtype A-and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations E Ndashimye, Y Li, PS Reyes, M Avino, AS Olabode, CM Kityo, ... Journal of Antimicrobial Chemotherapy 76 (11), 2965-2974, 2021 | 13 | 2021 |
| Evolution of protease inhibitor resistance in human immunodeficiency virus type 1 infected patients failing protease inhibitor monotherapy as second-line therapy in low-income … JA Thompson, C Kityo, D Dunn, A Hoppe, E Ndashimye, J Hakim, ... Clinical infectious diseases 68 (7), 1184-1192, 2019 | 11* | 2019 |
| Once vs twice-daily abacavir and lamivudine in African children V Musiime, P Kasirye, B Naidoo-James, P Nahirya-Ntege, T Mhute, ... Aids 30 (11), 1761-1770, 2016 | 11 | 2016 |
| New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates? E Ndashimye, PS Reyes, EJ Arts FEMS Microbiology Reviews 47 (1), fuac040, 2023 | 8 | 2023 |
| High Time to Start Human Immunodeficiency Virus Type 1–Infected Patients on Integrase Inhibitors in Sub-Saharan Africa E Ndashimye The Journal of Infectious Diseases 216 (2), 283-284, 2017 | 6 | 2017 |
| Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profiles HO Ajoge, TM Renner, K Bélanger, M Greig, S Dankar, HP Kohio, ... Nature Communications 14 (1), 16, 2023 | 4 | 2023 |
Eric ArtsProfessor, Department of Microbiology and Immunology, Western University在 uwo.ca 的电子邮件经过验证
